Literature DB >> 6317216

The role of partial hepatectomy and of promoters in the formation of tumors in non-target tissues of trans-4-acetylaminostilbene in rats.

D Hilpert, W Romen, H G Neumann.   

Abstract

After repeated administration of trans-4-acetylaminostilbene to rats, DNA-bound metabolites accumulate to the greatest extent in liver and kidney, which are considered to be nontarget tissues for this carcinogen. To test whether the persistent DNA adducts represent procarcinogenic lesions, an initiation-promotion experiment was carried out using trans-4-acetylaminostilbene as an initiator and phenobarbital, DDT and diethylstilbestrol as promoters. In addition, partial hepatectomy was performed in some groups. Partial hepatectomy alone or in combination with promoters led to the formation of preneoplastic enzyme deficient foci, hyperplastic nodules and hepatoma in great yields. In addition, mammary tumors were observed with diethylstilbestrol promotion. The results support our proposal that aminostilbene derivatives produce procarcinogenic DNA-lesions in many, if not all, tissues and that secondary factors determine when and where tumors arise.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6317216     DOI: 10.1093/carcin/4.12.1519

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  3 in total

Review 1.  The role of DNA damage in chemical carcinogenesis of aromatic amines.

Authors:  H G Neumann
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Tumors in rat kidney generated by initiation with trans-4-acetylaminostilbene and several promoting treatments.

Authors:  A Hoffmann; W Romen; H G Neumann
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 3.  Role of genotoxic and nongenotoxic effects in multistage carcinogenicity of aromatic amines.

Authors:  H G Neumann; R Hammerl; W Hillesheim; M Wildschütte
Journal:  Environ Health Perspect       Date:  1990-08       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.